-
1
-
-
33847025627
-
Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: A long-Term follow-up study
-
Saurenmann RK, Levin AV, Feldman BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: A long-Term follow-up study. Arthritis Rheum. 2007;56:647-657
-
(2007)
Arthritis Rheum
, vol.56
, pp. 647-657
-
-
Saurenmann, R.K.1
Levin, A.V.2
Feldman, B.M.3
-
3
-
-
80855138673
-
Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases
-
Miserocchi E, Pontikaki I, Modorati G, et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev. 2011;11:35-39
-
(2011)
Autoimmun Rev
, vol.11
, pp. 35-39
-
-
Miserocchi, E.1
Pontikaki, I.2
Modorati, G.3
-
4
-
-
22844450941
-
A prospective trial of infliximab therapy for refractory uveitis: Preliminary safety and efficacy outcomes
-
Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: Preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005; 123:903-912
-
(2005)
Arch Ophthalmol
, vol.123
, pp. 903-912
-
-
Suhler, E.B.1
Smith, J.R.2
Wertheim, M.S.3
-
5
-
-
33747856804
-
Tumor necrosis factor alpha inhibitors in the treatment of childhood uveitis
-
Saurenmann RK, Levin AV, Rose JB, et al. Tumor necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology. 2006;45:982-989
-
(2006)
Rheumatology
, vol.45
, pp. 982-989
-
-
Saurenmann, R.K.1
Levin, A.V.2
Rose, J.B.3
-
6
-
-
34248633648
-
Tumor necrosis factor-Alpha blocker in treatment of juvenile idiopathic arthritis-Associated uveitis refractory to second-line agents: Results of a multinational survey
-
Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factor-Alpha blocker in treatment of juvenile idiopathic arthritis-Associated uveitis refractory to second-line agents: Results of a multinational survey. J Rheumatol. 2007;34:1146-1150
-
(2007)
J Rheumatol
, vol.34
, pp. 1146-1150
-
-
Foeldvari, I.1
Nielsen, S.2
Kummerle-Deschner, J.3
-
7
-
-
66149093549
-
Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study
-
Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study. Ann Rheum Dis. 2009;68: 696-701
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 696-701
-
-
Rudwaleit, M.1
Rodevand, E.2
Holck, P.3
-
8
-
-
47949101475
-
Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric longterm prospective study of 163 patients
-
Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric longterm prospective study of 163 patients. Ann Rheum Dis. 2008;67:1145-1152
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 1145-1152
-
-
Gerloni, V.1
Pontikaki, I.2
Gattinara, M.3
Fantini, F.4
-
9
-
-
77953701867
-
Golimumab in patients with active rheumatoid arthritis despite methotrextae therapy: 52-week results of the goforward study
-
Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrextae therapy: 52-week results of the GOFORWARD study. Ann Rheum Dis. 2010;69:1129-1135
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 1129-1135
-
-
Keystone, E.1
Genovese, M.C.2
Klareskog, L.3
-
10
-
-
67650379733
-
Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor a inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial
-
Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor a inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009; 374:210-221
-
(2009)
Lancet
, vol.374
, pp. 210-221
-
-
Smolen, J.S.1
Kay, J.2
Doyle, M.K.3
-
11
-
-
68049099274
-
Golimumab, a human anti-Tumor necrosis factor a monoclonal antibody, injected subcutaneously every four weeks in methotrexate-nai?ve patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
-
Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-Tumor necrosis factor a monoclonal antibody, injected subcutaneously every four weeks in methotrexate-nai?ve patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60:2272-2283
-
(2009)
Arthritis Rheum
, vol.60
, pp. 2272-2283
-
-
Emery, P.1
Fleischmann, R.M.2
Moreland, L.W.3
-
12
-
-
10744230484
-
International league of associations for rheumatology classification of juvenile idiopathic arthritis: Second revision, edmonton, 2001
-
Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol. 2004;31:390-392
-
(2004)
J Rheumatol
, vol.31
, pp. 390-392
-
-
Petty, R.E.1
Southwood, T.R.2
Manners, P.3
-
13
-
-
24044463655
-
Standardization of uveitis nomenclature for reporting clinical data: Results of the first international workshop
-
The Standardization of Uveitis Nomenclature (SUN) working group
-
The Standardization of Uveitis Nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data: Results of the first international workshop. Am J Ophthalmol. 2005;140:509-516
-
(2005)
Am J Ophthalmol
, vol.140
, pp. 509-516
-
-
-
15
-
-
84869836247
-
Golimumab for the treatment of refractory juvenile idiopathic arthritisassociated uveitis
-
William M, Faez S, Papaliodis GN, Lobo AM. Golimumab for the treatment of refractory juvenile idiopathic arthritisassociated uveitis. J Ophthal Inflamm Infect. 2012;2:231-233
-
(2012)
J Ophthal Inflamm Infect
, vol.2
, pp. 231-233
-
-
William, M.1
Faez, S.2
Papaliodis, G.N.3
Lobo, A.M.4
-
16
-
-
84876004363
-
Behçet disease-Associated uveitis successfully treated with golimumab
-
Mesquida M, Hernandez MV, Llorenc V, et al. Behçet disease-Associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm. 2012;21:160-162
-
(2012)
Ocul Immunol Inflamm
, vol.21
, pp. 160-162
-
-
Mesquida, M.1
Hernandez, M.V.2
Llorenc, V.3
-
18
-
-
33846239331
-
Outcomes after switching from one anti-Tumor necrosis factor alpha agent to a second anti-Tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study
-
Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-Tumor necrosis factor alpha agent to a second anti-Tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum. 2007;56:13-20
-
(2007)
Arthritis Rheum
, vol.56
, pp. 13-20
-
-
Hyrich, K.L.1
Lunt, M.2
Watson, K.D.3
|